ACOG Releases New Guidance on GLP-1 Receptor Agonist Use During Pregnancy and Lactation

The American College of Obstetricians & Gynecologists (ACOG) has issued new guidance for clinicians on counseling patients about the use of GLP-1 receptor agonists before, during, and after pregnancy. The advisory highlights the lack of sufficient safety data in pregnancy and recommends considering discontinuation one to two months prior to conception, and against use during pregnancy.

Context

GLP-1 receptor agonists have gained popularity for their effectiveness in managing obesity and type 2 diabetes. However, there has been limited research on their effects during pregnancy and lactation. ACOG's advisory reflects a growing need for clarity in clinical practices as more women of reproductive age use these medications.

Why it matters

The new guidance from ACOG addresses the safety concerns surrounding the use of GLP-1 receptor agonists, which are commonly prescribed for weight management and diabetes. This is particularly important as these medications could impact maternal and fetal health. Clear recommendations help clinicians provide informed care and support to patients planning for pregnancy or who are already pregnant.

Implications

The guidance may lead to changes in prescription practices for GLP-1 receptor agonists, potentially reducing their use among women who are pregnant or planning to conceive. This could affect the management of obesity and diabetes in this demographic. Patients may need alternative treatment options, which could influence healthcare costs and access to care.

What to watch

Healthcare providers will likely adjust their counseling practices based on ACOG's recommendations. Monitoring how patients react to this guidance will be crucial, especially among those currently using or considering these medications. Future studies may emerge to better understand the long-term effects of GLP-1 receptor agonists in pregnant populations.